Kleanthis Xanthopoulos, Shoreline Biosciences CEO
Off Editas’ shelves, iNK cell therapies float to Shoreline
Editas Medicine is offloading its iNK cell franchise and licensing out some gene editing tech to a private biotech that counts …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
